Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial

Symptomatic Osteoarthritis of the Knee Clinical Trial

Official title:

Corticosteriods vs. Saline vs. Air Placebo Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02995083
• Other study ID #: 16090902
• Status: Withdrawn
• Phase: Early Phase 1
• First received: December 14, 2016
• Last updated: December 14, 2017
• Start date: June 2017
• Est. completion date: January 2018

Study information

• Verified date: December 2017
• Source: Rush University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the clinical benefit of intra-articular injections of saline in patients with symptomatic osteoarthritis of the knee and compare the clinical response of saline to the current standard treatment with corticosteroids and an air injection placebo.

Description:

As non-surgical treatments of OA are essential, multiple trials have been done to compare standard of care IA injection therapies to more novel injection treatments, with many of these trials using saline as the control arm. The purpose of using a control arm is to attempt to eliminate placebo effect and help distinguish the true effectiveness of a therapy. There has been controversy over the clinical effect of saline in treating OA with some arguing that saline may have some clinical benefit. If this is true, it could allow for the true effect of standard of care therapies to appear diminished when compared to saline as a placebo. A recent meta analysis looked at the use of saline as a placebo in 38 randomized control trials to determine if intra-articular saline injections for knee OA had a clinical effect. The study found that IA injections of saline significantly improved short-term knee pain in 32 of the studies which involved 1705 patients, p <0.001, and long-term pain was significantly decreased in 19 of the studies involving 1445 patients, p <0.001. It is essential to empirically determine if saline has a clinical effect due to the role it plays as a placebo in many clinical studies of the management of OA with intra-articular injections.

Objective: To investigate the clinical benefit of intra-articular injections of saline in patients with symptomatic osteoarthritis of the knee and compare the clinical response of saline to the current standard treatment with corticosteroids and an air injection placebo.

Study Design: Prospective, single-blinded, randomized, clinical study. Patients will be randomized into three treatment arms in a 1:1:1 fashion with approximately 50 patients in the saline arm, 50 patients in the corticosteroid arm, and 50 patients in the placebo arm.

Null Hypothesis: Clinical knee outcomes of subjects following one intra-articular knee injection of air will be similar to one intra-articular knee injection of saline or corticosteroid for symptomatic patients diagnosed with knee OA.

Statistical Assumptions: Power Analysis

Investigational Arm: 10 ml Saline (Normal Saline)

Control Arm: 1 ml of 40 mg corticosteroid in 9 ml 1% lidocaine (Depo-medrol, Pfizer, New York, New York), 10 ml air (placebo)

Primary Efficacy Endpoint: The primary efficacy endpoint is the mean change in the WOMAC Index score 12 weeks after first injection with regards to baseline score.

Secondary Efficacy Secondary efficacy endpoints include the change in the full Endpoints:

WOMAC Index, KOOS, Lysholm, IKDC, VAS, SF-12 and use of rescue medication (steroid at 12 weeks).

Enrollment: Prospective, randomized, clinical study designed to evaluate 150 subjects. All enrolled subjects will have a pre-procedure visit, one treatment visit, and follow-up visits at week 6 and week 12 if they require a rescue injection and will fill out patient reported outcome measures at 1, 6, 12, and 24 weeks.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. The patient must be between the ages of 18 and 80

2. Informed consent has been obtained from the patient

3. The patient must have diagnosed symptomatic osteoarthritis of the tibio-femoral or patello-femoral compartment of the target knee for at least 1 month

4. The patient has moderate-to-severe knee pain reflected by an average visual analogue scale (VAS) score of 4 or greater (out of a possible 10) over the previous 7 days.

5. Radiographic imaging must show grade II-III osteoarthritis on the Kellgren & Lawrence Scale.

6. Patients may have bilateral osteoarthritis but only patients with unilateral symptoms may be included.

Exclusion Criteria:

1. Knee instability

2. A score less than 4 (out of a possible 10) on their intake VAS

3. Major axial deviation (>5º valgus or varus deviation as evidenced on a standard of care x-ray.

4. Previous surgery at the target knee < 6 months.

5. Symptomatic osteoarthritis of the contralateral knee or any other joint.

6. Systemic or intra articular injection to any joint with corticosteroids within 6 months prior to screening

7. Previous joint injection of any type in the past 6 months

8. Systemic conditions that could interfere with outcome such as Rheumatoid arthritis, coagulopathy, and anemia.

9. Allergy to any of the injected substances.

10. Any patient unable to cease NSAID usage (other than low dose aspirin) due to unrelated condition.

11. Cognitive impairment or unable to provide informed consent

12. Recent knee trauma with violation of the intra-articular bone.

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee
• Symptomatic Osteoarthritis of the Knee

Intervention

Drug:
• 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
• Normal Saline 10 ml
Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
• Air 10 ml
Patients will receive an ultrasound guided intra-articular injection of Air 10 ml

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Rush University Medical Center

References & Publications (6)

Altman RD, Devji T, Bhandari M, Fierlinger A, Niazi F, Christensen R. Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Semin Arthritis Rheum. 2016 Oct;46(2):151-9. doi: 10.1016/j.semarthrit.2016.04.003. Epub 2016 Apr 27. Review. — View Citation

Eker HE, Cok OY, Aribogan A, Arslan G. The efficacy of intra-articular lidocaine administration in chronic knee pain due to osteoarthritis: A randomized, double-blind, controlled study. Anaesth Crit Care Pain Med. 2017 Apr;36(2):109-114. doi: 10.1016/j.accpm.2016.05.003. Epub 2016 Jul 30. — View Citation

Kim J, Seo BS. How to calculate sample size and why. Clin Orthop Surg. 2013 Sep;5(3):235-42. doi: 10.4055/cios.2013.5.3.235. Epub 2013 Aug 20. — View Citation

Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, Dragomir A, Kalsbeek WD, Luta G, Jordan JM. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008 Sep 15;59(9):1207-13. doi: 10.1002/art.24021. — View Citation

Williams VJ, Piva SR, Irrgang JJ, Crossley C, Fitzgerald GK. Comparison of reliability and responsiveness of patient-reported clinical outcome measures in knee osteoarthritis rehabilitation. J Orthop Sports Phys Ther. 2012 Aug;42(8):716-23. doi: 10.2519/jospt.2012.4038. Epub 2012 Mar 8. — View Citation

Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008 Dec;67(12):1716-23. doi: 10.1136/ard.2008.092015. Epub 2008 Jun 9. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in Western Ontario and McMaster Universities Arthritis Index score (WOMAC)	Mean change in the WOMAC Index score from baseline score	12 weeks after injection
Secondary	Mean change in Knee injury and Osteoarthritis Outcome Score (KOOS)	Mean change in the KOOS from baseline score	12 weeks after injection
Secondary	Mean change in International Knee Documentation Committee (IKDC) score	Mean change in IKDC from baseline score	12 weeks after injection
Secondary	Mean change in Visual Analogue Scale (VAS)	Mean change in VAS from baseline score	12 weeks after injection
Secondary	Mean change in Short Form 12 (SF-12) score	Mean change in SF-12 from baseline score	12 weeks after injection
Secondary	Mean change in The Lysholm Knee score	Mean change in The Lysholm Knee score from baseline score	12 weeks after injection
Secondary	Mean change in use of rescue medication	Use of anti-inflammatory, analgesics, and rescue corticosteroid injection. Number of pills taken each day. This will be collected via survey. If the medical examiner feels that the patient is continuing to do poorly and they did not receive the steroid injection intervention, then they will be offered a rescue corticosteroid injection at 12 weeks. The number of patients who do not initially receive a corticosteroid injection and require a rescue corticosteroid injection at 12 weeks will be recorded.	12 weeks after injection